302: Vertex's big deal, biotech's red numbers, & an industry history lesson
The Readout Loud
00:00
Introduction
Explore Vertex's unexpected entry into a large acquisition with Alpine Immune Sciences, focusing on a groundbreaking drug for an autoimmune kidney disease. The episode also hints at the effects of inflation on biotech stocks and hints at an upcoming surprise reveal.
Transcript
Play full episode
